CDC recommends approaches to maintain tuberculin skin testing during expected Aplisol shortage

The Centers for Disease Control and Prevention (CDC) has published recommendations addressing an expected shortage of Aplisol, a tuberculin skin test antigen. The publication type is listed as 'OTHER,' and key methodological details including study type, population, sample size, setting, and follow-up duration are not reported. No specific intervention or comparator was described in the available evidence.

The main finding is that the CDC recommends general approaches to prevent a reduction in tuberculin skin testing capability. No quantitative results, effect sizes, or outcome data are provided. Safety and tolerability information, including adverse events and discontinuations, are also not reported.

Key limitations include the absence of a formal study design and the lack of reported data on the effectiveness of the recommended approaches. The practice relevance is limited to awareness of official CDC guidance for contingency planning. Clinicians should consult the full CDC recommendations for specific operational details.